🔎 Trials Near Me

Home › Nerve Degeneration › NCT07224490

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

RecruitingPhase 1

Who can join

Ages 18 to 60 · All sexes

Full eligibility criteria
Inclusion Criteria

* Female (ages 18-45 years) or Male (ages 18-60 years)
* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration
* For women, negative serum hCG pregnancy test
* For cases, diagnosis of post-covid-19 syndrome
* For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome

Exclusion Criteria

* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results
* Active use of illicit drugs (not including marijuana)
* For women,
* Pregnant
* Trying to become pregnant during protocol participation
* Breast feeding
* Surgical or natural menopause

About the study

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

What is being tested

Sponsor: Stephanie B. Seminara, MD · Participants: 40 · Started: Mar 10, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07224490

Locations in the U.S.

MassachusettsMassachusetts General Hospital, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.